Portuguese startup PFx Biotech has raised €2.5 million in a seed funding spherical led by Buenavista Fairness Companions, with assist from EIT Meals and Beta Capital. The corporate has additionally secured a €2.5 million grant from the European Innovation Council and SMEs Government Company (EISMEA), taking the full quantity it has raised to €5 million.
PFx Biotech is targeted on producing extremely purposeful bioidentical human milk proteins via precision fermentation. The intention is to supply sustainable, non-GMO, and allergen-free dietary options for all life levels, together with infants, athletes, and the aged.
The brand new capital shall be used to fund bespoke lab services, an expanded crew, and the pre-industrial scale-up of PFx Biotech’s lactoferrin. On LinkedIn, the startup says it’s now open to strategic partnerships in R&D, scale-up, and commercialization.
“Defining second”
PFx Biotech is amongst a number of corporations worldwide which can be working to supply options to human milk. For instance:
- Checkerspot has developed a human breast milk fats analog utilizing microalgae fermentation.
- Yali Bio and The Live Green Co have each produced human milk fats analogs utilizing yeast.
- Helaina raised $45 million final 12 months to commercialize precision-fermented human lactoferrin.
- TurtleTree has additionally developed precision-fermented lactoferrin, receiving FDA clearance for the ingredient final month.
- Nūmi is growing cultivated breast milk.
“It is a defining second for PFx Biotech,” stated Ali Osman, founder and CEO of PFx Biotech. “We’re proud to be backed by mission–aligned traders to assist us unlock the potential of lactoferrin in a extra sustainable diet mannequin. As we enter this new progress stage, we’re actively exploring strategic collaborations throughout R&D, scale-up, and go-to-market alternatives.”
